News

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice settings, according to Dustin D. French, PhD.

Broadwood and Yunqi Capital will add 3 total members to the board, while the CEO and more step down.

A total of 38 patients were included in the study. All underwent implantation of the PRIMAretinal prosthetic chip with the goal of restoring vision.

The trial is evaluating OCU410 (AAV5-RORA) for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, AMD, and rare eye diseases.

OCU410ST uses an adeno-associated virus delivery platform for the retinal delivery of the RORA gene.

Formerly, the EDOF technology was specifically limited to intraocular lenses.

Patients underwent a full ophthalmologic examination that included optical coherence tomography (OCT), OCT angiography, and biometry.

The Investigational New Drug (IND) application from Complement Therapeutics for CTx001 was previously approved by the FDA in October 2025

“Remarkable” results were reportedly obtained with hypotony with hydroxypropyl methylcellulose.

The Part B dose-expansion portion is evaluating SB-007 for the treatment of Stargardt disease.

As Glaucoma Awareness Month highlights evolving practice, specialists describe how artificial intelligence, sustained drug delivery, laser therapy, and workflow integration are reshaping earlier, more individualized glaucoma care.

The JADE clinical study enrolled more than 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD).

Optoretinography is an emerging technology used to test light-evoked photoreceptor activity.

Their conversation focuses on anatomy-driven, individualized approaches and multidisciplinary decision-making for patients with neovascular glaucoma.

Researchers uncover a DNA repair mechanism in Greenland sharks that preserves their vision for centuries, offering insights into longevity and eye health.

Harvard researchers used data to shed light on pediatric neurotrophic keratopathy, revealing key insights into prevalence, vision outcomes, and treatment approaches.

According to the company, the FDA’s decision was supported by visual function results from the phase 2 ACUITY trial in ON.

The company did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held on January 6, 2026.

A recent study reveals significant ocular complications from monkeypox, highlighting the need for enhanced eye health strategies in affected regions.

A recent study represents a step forward in investigations of the retinal layers as they are affected by glaucoma.

Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.